Felix Hammann

2.1k total citations
47 papers, 1.1k citations indexed

About

Felix Hammann is a scholar working on Infectious Diseases, Computational Theory and Mathematics and Molecular Biology. According to data from OpenAlex, Felix Hammann has authored 47 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 10 papers in Computational Theory and Mathematics and 9 papers in Molecular Biology. Recurrent topics in Felix Hammann's work include Computational Drug Discovery Methods (10 papers), Parasitic Diseases Research and Treatment (7 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Felix Hammann is often cited by papers focused on Computational Drug Discovery Methods (10 papers), Parasitic Diseases Research and Treatment (7 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Felix Hammann collaborates with scholars based in Switzerland, Spain and United Kingdom. Felix Hammann's co-authors include Jürgen Drewe, Carlos Chaccour, Claudia Suenderhauf, Jörg Huwyler, Christoph Helma, Stephan Krähenbühl, Heike Gutmann, N. Regina Rabinovich, Verena Schöning and Matthias E. Liechti and has published in prestigious journals such as Scientific Reports, Journal of Controlled Release and Molecules.

In The Last Decade

Felix Hammann

44 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Felix Hammann Switzerland 20 213 211 200 149 129 47 1.1k
Pascal Houzé France 23 467 2.2× 66 0.3× 71 0.4× 321 2.2× 24 0.2× 134 1.9k
S. Casey Laizure United States 21 281 1.3× 146 0.7× 112 0.6× 50 0.3× 26 0.2× 53 1.4k
Bo Tan China 21 340 1.6× 111 0.5× 41 0.2× 253 1.7× 18 0.1× 78 1.5k
Börje Darpö United States 30 1.2k 5.7× 227 1.1× 163 0.8× 92 0.6× 39 0.3× 119 3.1k
Elisabet I. Nielsen Sweden 28 367 1.7× 45 0.2× 332 1.7× 142 1.0× 31 0.2× 93 2.7k
Örjan Ericsson Sweden 25 220 1.0× 76 0.4× 106 0.5× 659 4.4× 59 0.5× 84 1.8k
Helen Winter United States 25 329 1.5× 56 0.3× 469 2.3× 72 0.5× 49 0.4× 69 1.9k
Tajamul Hussain Saudi Arabia 24 721 3.4× 179 0.8× 101 0.5× 129 0.9× 49 0.4× 133 2.4k
V. Navaratnam Malaysia 19 168 0.8× 161 0.8× 130 0.7× 444 3.0× 12 0.1× 45 1000
Gordon McKay Canada 17 436 2.0× 57 0.3× 127 0.6× 71 0.5× 47 0.4× 23 2.1k

Countries citing papers authored by Felix Hammann

Since Specialization
Citations

This map shows the geographic impact of Felix Hammann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix Hammann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix Hammann more than expected).

Fields of papers citing papers by Felix Hammann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felix Hammann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix Hammann. The network helps show where Felix Hammann may publish in the future.

Co-authorship network of co-authors of Felix Hammann

This figure shows the co-authorship network connecting the top 25 collaborators of Felix Hammann. A scholar is included among the top collaborators of Felix Hammann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felix Hammann. Felix Hammann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roth, Beat, Felix Hammann, Damien Jacot, et al.. (2024). UROPOT: study protocol for a randomized, double-blind phase I/II trial for metabolism-based potentiation of antimicrobial prophylaxis in the urological tract. Trials. 25(1). 682–682. 2 indexed citations
2.
Hammann, Felix, Vera van der Velpen, Chin B. Eap, et al.. (2024). Pharmacokinetics and Pharmacodynamics of Inhaled Nicotine Salt and Free-Base Using an E-cigarette: A Randomized Crossover Study. Nicotine & Tobacco Research. 26(10). 1313–1321. 8 indexed citations
3.
Schöning, Verena, Sarah Dräger, Katharina Rentsch, et al.. (2024). Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection. Journal of Antimicrobial Chemotherapy. 79(8). 2031–2039.
4.
Ngama, Mwanajuma, Urs Duthaler, Felix Hammann, et al.. (2024). Mosquitocidal efficacy and pharmacokinetics of single-dose ivermectin versus three-day dose regimen for malaria vector control compared with albendazole and no treatment: An open-label randomized controlled trial. International Journal of Infectious Diseases. 148. 107236–107236. 2 indexed citations
5.
6.
Schöning, Verena & Felix Hammann. (2022). Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients. Pharmaceutics. 14(9). 1828–1828.
7.
Schöning, Verena, et al.. (2022). Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study. Frontiers in Pharmacology. 13. 816429–816429. 6 indexed citations
8.
Duthaler, Urs, Michael Weber, Carlos Chaccour, et al.. (2021). The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes. PLoS Pathogens. 17(3). e1009382–e1009382. 4 indexed citations
9.
Drewe, Jürgen, et al.. (2021). Modeling Structure–Activity Relationship of AMPK Activation. Molecules. 26(21). 6508–6508. 6 indexed citations
10.
Duthaler, Urs, et al.. (2021). Potential metabolic resistance mechanisms to ivermectin in Anopheles gambiae: a synergist bioassay study. Parasites & Vectors. 14(1). 172–172. 10 indexed citations
11.
Schöning, Verena, Evangelia Liakoni, Christine Baumgartner, et al.. (2021). Development and validation of a prognostic COVID-19 severity assessment (COSA) score and machine learning models for patient triage at a tertiary hospital. Journal of Translational Medicine. 19(1). 56–56. 36 indexed citations
12.
Chaccour, Carlos, Gloria Abizanda, Aina Casellas, et al.. (2020). Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. Scientific Reports. 10(1). 17073–17073. 31 indexed citations
13.
Chaccour, Carlos, Felix Hammann, & N. Regina Rabinovich. (2017). Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malaria Journal. 16(1). 161–161. 83 indexed citations
14.
Chaccour, Carlos, Felix Hammann, Gloria Abizanda, et al.. (2017). Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae. Scientific Reports. 7(1). 8535–8535. 25 indexed citations
15.
Dolder, Patrick C., Petra Strajhar, Patrick Vizeli, et al.. (2017). Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects. Frontiers in Pharmacology. 8. 617–617. 37 indexed citations
16.
17.
Hammann, Felix & Jürgen Drewe. (2014). Data mining for potential adverse drug–drug interactions. Expert Opinion on Drug Metabolism & Toxicology. 10(5). 665–671. 15 indexed citations
18.
Hammann, Felix & Jürgen Drewe. (2012). Decision tree models for data mining in hit discovery. Expert Opinion on Drug Discovery. 7(4). 341–352. 19 indexed citations
19.
Hammann, Felix, Heike Gutmann, Nicole P. Vogt, Christoph Helma, & Jürgen Drewe. (2010). Prediction of Adverse Drug Reactions Using Decision Tree Modeling. Clinical Pharmacology & Therapeutics. 88(1). 52–59. 78 indexed citations
20.
Hammann, Felix, et al.. (2009). Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein. Current Drug Metabolism. 10(4). 339–346. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pascal Houzé Breakdown of academic impact, for papers by S. Casey Laizure Breakdown of academic impact, for papers by Bo Tan Breakdown of academic impact, for papers by Börje Darpö Breakdown of academic impact, for papers by Elisabet I. Nielsen Breakdown of academic impact, for papers by Örjan Ericsson Breakdown of academic impact, for papers by Helen Winter Breakdown of academic impact, for papers by Tajamul Hussain Breakdown of academic impact, for papers by V. Navaratnam Breakdown of academic impact, for papers by Gordon McKay
Rankless by CCL
2026